GTS Securities LLC Lowers Position in BioNTech SE (NASDAQ:BNTX)

GTS Securities LLC reduced its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 93.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,937 shares of the company's stock after selling 28,048 shares during the quarter. GTS Securities LLC's holdings in BioNTech were worth $221,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of BNTX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of BioNTech by 19.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company's stock worth $25,192,000 after buying an additional 36,746 shares during the period. USS Investment Management Ltd purchased a new position in shares of BioNTech in the fourth quarter valued at about $3,117,000. Tema Etfs LLC bought a new position in shares of BioNTech during the fourth quarter valued at about $513,000. Stempoint Capital LP purchased a new stake in shares of BioNTech during the fourth quarter worth about $6,997,000. Finally, Shell Asset Management Co. purchased a new stake in shares of BioNTech during the fourth quarter worth about $2,215,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a report on Friday. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $134.00 target price on shares of BioNTech in a report on Thursday, May 22nd. JPMorgan Chase & Co. dropped their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $139.14.

BioNTech Stock Up 2.5%

BNTX traded up $2.83 during midday trading on Tuesday, reaching $115.93. The company's stock had a trading volume of 2,610,062 shares, compared to its average volume of 935,125. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The stock's 50-day moving average is $97.78 and its 200-day moving average is $108.21. The firm has a market capitalization of $27.87 billion, a price-to-earnings ratio of -55.20 and a beta of 1.35. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The firm's quarterly revenue was down 19.5% compared to the same quarter last year. As a group, research analysts expect that BioNTech SE will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.